Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
Sarah GreeneYvette RobbinsWojciech K MydlarzAngel P HuynhNicole C SchmittJay FriedmanLucas A HornClaudia PalenaJeffrey SchlomDean Y MaedaJohn A ZebalaPaul E ClavijoClint AllenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
The clinical study of CXCR1/2 inhibitors in combination with adoptively transferred NK cells is warranted.